Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Review documents show that FDA crafted the calcimimetic's label with the expectation of off-label use in secondary hyperparathyroidism patients not yet on dialysis. Concern about Sensipar's potential to cause QT prolongation via hypocalcemia was a key factor in FDA's rejection of Amgen's request for approval in the pre-dialysis population.

You may also be interested in...

Sensipar Label Has Precautions On Hypocalcemia; Pre-Dialysis Indication Could Be Challenge

Amgen's chronic kidney disease treatment Sensipar includes precautions on hypocalcemia

Spectrum’s Iso-Vorin Could Clear FDA For Osteosarcoma By First Quarter

The Irvine, Calif., firm also plans sNDAs for a colorectal cancer claim and an oral formulation of the leucovorin relative.

Thelin's Third "Approvable" Letter Recommends Additional Clinical Trial

Encysive may be forced to make "significant reductions" to infrastructure and workforce, firm says June 15.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts